News & Blog

LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)

Meet the Community – David (Dave) Arnold

Meet the Community – Leila Filgueiras

Meet The Community: Nikolaos Kotsomouras

Meet The Community: Scott Armit

Meet The Community: Silvana Camaj

Meet The Community: Silvany Guimarães Coelho Cotting

Larimar Therapeutics Announces $95 Million Private Placement Financing

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Meet The Community: Emily Young

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results